Transcode Therapeutics Inc

NASDAQ:RNAZUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

TransCode Therapeutics, Inc. is a ribonucleic acid (RNA) oncology company. Its lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), a regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and several others. Its preclinical programs include two solid tumor programs, TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 (PD-L1), and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. It also has two indication agnostic programs, TTX-RIGA, an RNA-based agonist of the retinoic acid- inducible gene I (RIG-I), targeting activation of innate immunity in the tumor microenvironment, and TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells, as well as TTX-mRNA, a tumor-type specific mRNA-based platform for the development of cancer vaccines that are designed to activate cytotoxic immune responses.

Contact Information

Headquarters

6 Liberty Square, #2382BOSTON, MA, United States 02109

Phone

857-301-6857

Fax

302-655-5049

Executives

Independent Chairman of the Board

Philippe Calais

President, Chief Executive Officer, Co-Founder, Director

Robert Michael Dudley

Chief Financial Officer, Vice President, Director

Thomas Fitzgerald

Independent Director

Erik Manting

Independent Director

Magda Marquet